Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. ANGO
stocks logo

ANGO

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Financial AI Agent
Financial AI Agent

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2026Q2
FY2026Q3
FY2026Q4
76.31M
+4.76%
-0.098
+143.75%
76.59M
+6.37%
-0.090
-400%
81.68M
+1.89%
-0.035
+16.67%
Estimates Revision
The market is revising Upward the revenue expectations for AngioDynamics, Inc. (ANGO) for FY2026, with the revenue forecasts being adjusted by 0.58% over the past three months. During the same period, the stock price has changed by 26.93%.
Revenue Estimates for FY2026
Revise Upward
up Image
+0.58%
In Past 3 Month
EPS Estimates for FY2026
Revise Upward
up Image
+4.88%
In Past 3 Month
Stock Price
Go Up
up Image
+26.93%
In Past 3 Month
Wall Street analysts forecast ANGO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ANGO is 19.33 USD with a low forecast of 16.00 USD and a high forecast of 24.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
Wall Street analysts forecast ANGO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ANGO is 19.33 USD with a low forecast of 16.00 USD and a high forecast of 24.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 13.620
sliders
Low
16.00
Averages
19.33
High
24.00
Current: 13.620
sliders
Low
16.00
Averages
19.33
High
24.00
Canaccord
John Young
Buy
maintain
$15 -> $17
2025-07-16
Reason
Canaccord
John Young
Price Target
$15 -> $17
2025-07-16
maintain
Buy
Reason
Canaccord analyst John Young raised the firm's price target on AngioDynamics to $17 from $15 and keeps a Buy rating on the shares. The firm said the company had another well-executed quarter, driven by growth in its Med-Tech business with nice beats across the board. Med-Tech, Med-Device, total revenues, adj. EBITDA and adj. EPS all beat estimates, capping off a momentum-building year for the company and there wasn't much thesis changing news for the company during the quarter.
Lake Street
Buy
initiated
$24
2025-07-16
Reason
Lake Street
Price Target
$24
2025-07-16
initiated
Buy
Reason
Lake Street initiated coverage of AngioDynamics with a Buy rating and $24 price target. The firm says the company has transformed its portfolio into faster-growth and higher-margin cardiovascular and cancer treatment products. The Street is missing AngioDynamics' strategic realignment as the shares should be valued more in line with higher multiple medical technology companies, the analyst tells investors in a research note.
HC Wainwright & Co.
Yi Chen
Strong Buy
Maintains
$15 → $16
2025-04-07
Reason
HC Wainwright & Co.
Yi Chen
Price Target
$15 → $16
2025-04-07
Maintains
Strong Buy
Reason
HC Wainwright & Co.
Yi Chen
Strong Buy
Maintains
$14 → $15
2025-01-10
Reason
HC Wainwright & Co.
Yi Chen
Price Target
$14 → $15
2025-01-10
Maintains
Strong Buy
Reason
HC Wainwright & Co.
Yi Chen
Strong Buy
Reiterates
$14
2024-12-10
Reason
HC Wainwright & Co.
Yi Chen
Price Target
$14
2024-12-10
Reiterates
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for AngioDynamics Inc (ANGO.O) is -55.21, compared to its 5-year average forward P/E of -102.89. For a more detailed relative valuation and DCF analysis to assess AngioDynamics Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-102.89
Current PE
-55.21
Overvalued PE
273.20
Undervalued PE
-478.98

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-6.52
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
178.57
Undervalued EV/EBITDA
-191.62

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
1.78
Current PS
0.00
Overvalued PS
2.64
Undervalued PS
0.92
AI Stock Picker
AI Stock Picker

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

ANGO News & Events

Events Timeline

(ET)
2025-10-02
06:04:49
AngioDynamics updates FY26 adjusted EPS forecast to a range of (33c)-(23c) from (35c)-(25c)
select
2025-10-02
06:03:03
AngioDynamics announces Q1 adjusted EPS of 10 cents, below consensus estimate of 12 cents.
select
2025-07-28 (ET)
2025-07-28
08:36:16
AngioDynamics enrolls first patient in Auryon Atherectomy combination study
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
5.0
10-29MarketWatch
Seven Tech Stocks Experience Significant Insider Selling Despite Price Increases

  • Insider Sentiment: Corporate insiders are exhibiting a high level of bearish sentiment, the most pessimistic since 1974.

  • Sell/Buy Ratio: The recent sell/buy ratio for all exchanges reached 17.32, indicating a strong bearish outlook, as values above 6 are considered bearish.

[object Object]
Preview
1.0
10-28Newsfilter
AngioDynamics to Take Part in UBS Global Healthcare Conference

  • Company Announcement: AngioDynamics, Inc. will have its President and CEO, Jim Clemmer, and CFO, Stephen Trowbridge, participate in a fireside chat at the UBS Global Healthcare Conference on November 10, 2025, at 8:00 a.m. ET.

  • Webcast Availability: A live webcast of the fireside chat will be available on the "Investors" section of AngioDynamics' website and will be accessible for replay after the event.

  • Company Focus: AngioDynamics is dedicated to restoring healthy blood flow, expanding cancer treatment options, and enhancing patient quality of life through innovative medical technologies.

  • Market Position: The company’s devices are utilized by skilled physicians in rapidly growing healthcare markets to address unmet patient needs.

[object Object]
Preview
3.5
10-13Newsfilter
AngioDynamics' NanoKnife® System Recognized in TIME's 2025 Best Inventions List

  • Recognition of NanoKnife System: AngioDynamics' NanoKnife System has been named one of TIME's 2025 Best Inventions for its innovative use of Irreversible Electroporation (IRE) technology in treating prostate tumors, offering a minimally invasive alternative to traditional cancer treatments.

  • Clinical Efficacy and Safety: The NanoKnife System has shown promising results in clinical studies, with 84% of patients free from significant disease after 12 months and high preservation rates of urinary and sexual function, supporting its FDA clearance for prostate tissue ablation.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is AngioDynamics Inc (ANGO) stock price today?

The current price of ANGO is 13.62 USD — it has increased 0.96 % in the last trading day.

arrow icon

What is AngioDynamics Inc (ANGO)'s business?

AngioDynamics, Inc. is a transformative medical technology company. The Company is focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving quality of life for patients. It designs, manufactures, and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Its devices are generally used in minimally invasive, image-guided procedures. Its segments include Med Tech and Med Device. Its product categories include oncology, venous therapies, vascular interventions, and ports. Its oncology products include Model 1500X RF Generator, IsoLoc Endorectal Balloon, Habib 4X Laparoscopic Bipolar Resection Device, Habib 4X Bipolar Resection Device, and Alatus. Its venous therapies include VenaCure EVLT 1470 Pro Laser, VenaCure EVLT System, VenaCure EVLT Procedure Packs, and others.

arrow icon

What is the price predicton of ANGO Stock?

Wall Street analysts forecast ANGO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ANGO is 19.33 USD with a low forecast of 16.00 USD and a high forecast of 24.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is AngioDynamics Inc (ANGO)'s revenue for the last quarter?

AngioDynamics Inc revenue for the last quarter amounts to 75.71M USD, increased 12.18 % YoY.

arrow icon

What is AngioDynamics Inc (ANGO)'s earnings per share (EPS) for the last quarter?

AngioDynamics Inc. EPS for the last quarter amounts to -0.26 USD, decreased -16.13 % YoY.

arrow icon

What changes have occurred in the market's expectations for AngioDynamics Inc (ANGO)'s fundamentals?

The market is revising Upward the revenue expectations for AngioDynamics, Inc. (ANGO) for FY2026, with the revenue forecasts being adjusted by 0.58% over the past three months. During the same period, the stock price has changed by 26.93%.
arrow icon

How many employees does AngioDynamics Inc (ANGO). have?

AngioDynamics Inc (ANGO) has 675 emplpoyees as of December 05 2025.

arrow icon

What is AngioDynamics Inc (ANGO) market cap?

Today ANGO has the market capitalization of 561.14M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free